Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hewei Anchang Formula Granules is a Traditional Chinese Medicine (TCM) herbal formulation developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is specifically designed for the treatment of patients presenting with overlapping symptoms of functional dyspepsia (FD) and diarrhea-predominant irritable bowel syndrome (IBS-D). The formula is based on the TCM principle of 'treating different diseases with the same therapeutic approach,' targeting liver-stomach disharmony and liver stagnation-spleen deficiency syndromes. Mechanistically, the formula is intended to exert holistic regulatory effects by modulating the gut microbiota and the neuroendocrine-immune network.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hewei Anchang Formula Granules.